| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 03/04/2004 | US20040043008 Dissociation muscle tissues; culturing; accumulation |
| 03/04/2004 | CA2495952A1 Preventive therapeutic composition for muscular fatigue, pulled muscle and disease attributed thereto |
| 03/04/2004 | CA2495376A1 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
| 03/03/2004 | EP1394178A1 Peptide fragments of myelin basic protein, their pharmaceutical compositions and their use in treating multiple sclerosis |
| 03/03/2004 | EP1392852A2 Nucleic acid-associated proteins |
| 03/03/2004 | EP1392844A2 Use of hmg fragments as anti-inflammatory agents |
| 03/03/2004 | EP1392699A1 6h-oxazolo 4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 03/03/2004 | EP1392696A1 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro 2,3-b]quinolin-4-yl)-2-(2- oxopyrrolidin -1 -yl)acetamide |
| 03/03/2004 | EP1392662A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| 03/03/2004 | EP1392644A1 Cinnamide derivatives as kcnq potassium channel modulators |
| 03/03/2004 | EP1392643A2 Trisubstituted-n- (1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors |
| 03/03/2004 | EP1392641A1 Substituted cyclohexane-1,4-diamine derivatives |
| 03/03/2004 | EP1392366A1 Nuclear receptor-mediated introduction of a pna into cell nuclei |
| 03/03/2004 | EP1392311A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 03/03/2004 | EP1392307A1 Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
| 03/03/2004 | EP1392300A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors |
| 03/03/2004 | EP1392297A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases |
| 03/03/2004 | EP1392289A2 Caspase inhibitors and uses thereof |
| 03/03/2004 | EP1392276A1 Potentiation of therapeutic effects of polyunsaturated fatty acids |
| 03/03/2004 | EP1392264A1 Delivery of antiemetics through an inhalation route |
| 03/03/2004 | EP1392262A1 Delivery of drug esters through an inhalation route |
| 03/03/2004 | EP1392261A2 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 03/03/2004 | EP1392259A2 Delivery of erectile dysfunction drugs through an inhalation route |
| 03/03/2004 | EP1392257A1 Delivery of antihistamines through an inhalation route |
| 03/03/2004 | EP1392133A2 Functional agent for decomposing nicotine and method of preparing the same |
| 03/03/2004 | EP1196440B1 Therapeutic peptides derived from subsequences of bpi |
| 03/03/2004 | EP1124797B1 N-arylsulfonyl amino acid omega amides |
| 03/03/2004 | EP1047437A4 Sea cucumber carotenoid lipid fraction products and methods of use |
| 03/03/2004 | CN1479736A Benzofuran and benzothiophene derivatives |
| 03/03/2004 | CN1479715A Amide for inhibition of IL-8-induced chemiotaxis of neutrophil leucocytes |
| 03/02/2004 | US6699867 4-(4-Methyl-piperazin-1-ylmethyl)-4,5-dihydrothiazol-2-ylamine |
| 03/02/2004 | US6699865 Protein kinase inhibitors, for treating cancer inflammatory disorders, restenosis, and cardiovascular disease. |
| 03/02/2004 | US6699856 Pyrazinones, compositions containing such compounds and methods of use |
| 02/26/2004 | WO2004016608A1 Novel quinuclidine derivatives and their use |
| 02/26/2004 | WO2004016593A1 Diaryl compounds as monoamine reuptake inhibitors |
| 02/26/2004 | WO2004016083A1 Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy |
| 02/26/2004 | WO2004004763A3 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 02/26/2004 | WO2003097564A3 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
| 02/26/2004 | WO2003088985A3 Use of compositions containing petasites for treating diseases |
| 02/26/2004 | WO2003088970A3 Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| 02/26/2004 | WO2003087333A3 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 02/26/2004 | WO2003074008A3 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 02/26/2004 | WO2003060085A3 Mammalian neural stem cells, compositions and uses thereof |
| 02/26/2004 | WO2003026568A3 Androstanes as androgen receptor modulators |
| 02/26/2004 | WO2002057211A8 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 02/26/2004 | WO2002055075A9 Compounds and methods for regulating cell differentiation |
| 02/26/2004 | US20040039066 Administering hydroxytyrosol and oleuropein in a ratio of 1:1-200:1 |
| 02/26/2004 | US20040039058 Identifying a mammal having elevated concentrations of tumor necrosis factor- alpha and administering stearidonic acid (18:4, n-3) over a time period |
| 02/26/2004 | US20040039025 Substituted hydrazine derivatives |
| 02/26/2004 | US20040038976 S,N-diarylsulfonamide derivatives; treating inflammatory diseases such as Celiac's disease, Crohn's disease or colitis. |
| 02/26/2004 | US20040038887 Copolymers for suppression of autoimmune diseases, and methods of use |
| 02/26/2004 | US20040038402 Gene therapy; for production of transgenic animal models |
| 02/26/2004 | US20040038339 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 02/26/2004 | US20040038293 Antibodies to human cd154 |
| 02/26/2004 | US20040038265 Using low density lipoprotein related proteins (LRP) to diagnose, treat and prevent paget's, osteoporosis, cirrhosis and rickets |
| 02/26/2004 | DE10232020A1 Neurorezeptoraktive Heteroarencarboxamide Neuroreceptor Active Heteroarencarboxamide |
| 02/26/2004 | CA2495409A1 Diaryl compounds as monoamine reuptake inhibitors |
| 02/26/2004 | CA2493245A1 Novel quinuclidine derivatives and their use |
| 02/25/2004 | EP1391458A2 Novel method for producing 5-aryloxymethyl-2-oxazolidinones |
| 02/25/2004 | EP1390508A2 A retinoic acid metabolizing cytochrome p450 |
| 02/25/2004 | EP1390496A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 02/25/2004 | EP1390493A1 Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
| 02/25/2004 | EP1390483A2 Gene encoding molecular motor protein and diagnosis method for the disease related to the gene |
| 02/25/2004 | EP1390400A2 Pharmaceutical use for secreted bacterial effector proteins |
| 02/25/2004 | EP1390391A1 Transporters and ion channels |
| 02/25/2004 | EP1390385A2 Nucleic acid based modulation of female reproductive diseases and conditions |
| 02/25/2004 | EP1390361A2 Melanocortin receptor ligands |
| 02/25/2004 | EP1390353A1 Triazole-derived kinase inhibitors and uses thereof |
| 02/25/2004 | EP1390054A2 Mu-conopeptides |
| 02/25/2004 | EP1390021A1 Delivery of compounds for the treatment of migraine through an inhalation route |
| 02/25/2004 | EP1263756B1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 02/25/2004 | EP1210326B1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/25/2004 | EP1200409B1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 02/25/2004 | EP1140931B1 5ht1 antagonists for antidepressant therapy |
| 02/25/2004 | EP1087934B1 Aminocyclohexyl ether compounds and uses thereof |
| 02/25/2004 | EP1042296B1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 02/25/2004 | EP1037612B1 Pharmaceutical compositions containing micronized bicyclic drugs |
| 02/25/2004 | EP1032402B1 Use of citicoline for the treatment of multiple sclerosis (MS) |
| 02/25/2004 | CN1478098A Modulation of IL-2-and IL-15-mediated T cell responses |
| 02/25/2004 | CN1478087A Indolylmaleimide derivatives as protein kinase C inibitors |
| 02/25/2004 | CN1478080A Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 02/25/2004 | CN1477968A Methods for treating rheumatic diseases using soluble CTLA4 molecule |
| 02/25/2004 | CN1477960A EPA receptor inhibitors to treat rheumatoid arthritis |
| 02/25/2004 | CN1139588C Novel fluorinated imidazoline benzodioxane, preparation and therapeutic use thereof |
| 02/24/2004 | US6696567 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/24/2004 | US6696495 Treatment of disorders secondary to organic impairments |
| 02/24/2004 | US6696464 Triazolo-pyridines anti-inflammatory compounds |
| 02/24/2004 | US6696427 Use of bisphosphonates for the prevention and treatment of infectious processes |
| 02/19/2004 | WO2004015106A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 02/19/2004 | WO2004014920A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | WO2004014911A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014903A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 02/19/2004 | WO2004014825A1 Cannabinoid receptor ligands |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014415A1 Growth hormone releasing peptides |
| 02/19/2004 | WO2004014414A1 Novel uses of rfrp and ot7t022 |
| 02/19/2004 | WO2004014405A1 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |